公开(公告)号：US3644368A

公开(公告)日：1972-02-22

申请号：US78639868

申请日：1968-12-23

Applicant: ROUSSEL UCLAF

Inventor： ALLAIS ANDRE ,  MEIER JEAN

IPC: C07D215/18 ,  C07D215/22 ,  C07D215/233 ,  C07D215/44 ,  C07D33/52

CPC classification number: C07D215/233 ,  C07D215/18 ,  C07D215/44

Abstract: NOVLE 4 - (ORTHOR-(2'',3''-DIHYDROXYPROPYLOXYCARBONYL)PHENYL)-AMINO-QUINOLINES OF THE FORMULA

4-((2-(R''-O-CH2-CH(-O-R)-CH2-OOC-)PHENYL)-NH-),CF3-

QUINOLINE

WHEREIN THE CF3 RADICAL IS IN THE 7 OR 8-POSITION, R AND R'' ARE HYDROGEN AND TAKEN TOGETHER FORM A KETONIDE OF THE FORMULA

-C(-P)(-Q)-

P AND O BEING SELECTED FROM THE GROUP COSISTING OF ALKYL ARALKYL AND ARYL AND THE NON-TOXIC, PHARMACEUTICALLY ACCEPTABLE ADDITION SALTS WHEN R AND R'' ARE HYDROGEN'', WHICH POSSESS NOTABLE ANTI-INFLAMMATORY ACTIVITY AND INTENSE ANALGESIC ACTIVITY.

Abstract translation: 下式的新型4- [邻 - （2'，3'-二羟基丙氧基羰基） - 苯基] - 氨基 - 喹啉CF 3基团在七或八位，R和R'是氢并且一起形成酮 当R和R'是氢时，式P和Q选自烷基芳烷基和芳基以及无毒的药学上可接受的加成盐，其具有显着的抗炎活性和强烈的镇痛活性。

公开(公告)号：US3502681A

公开(公告)日：1970-03-24

申请号：US3502681D

申请日：1968-04-10

Applicant: ROUSSEL UCLAF

Inventor： ALLAIS ANDRO ,  MEIER JEAN

IPC: C07D215/44 ,  C07D33/52

CPC classification number: C07D215/44

公开(公告)号：US3445469A

公开(公告)日：1969-05-20

申请号：US3445469D

申请日：1966-02-01

Applicant: ROUSSEL UCLAF

Inventor： ALLAIS ANDRE ,  GIRAULT PIERRE

IPC: C07D215/44 ,  C07D33/48 ,  A61K27/00

CPC classification number: C07D215/44

公开(公告)号：US2474823A

公开(公告)日：1949-07-05

申请号：US62690845

申请日：1945-11-05

Applicant: PARKE DAVIS & CO

Inventor： BURCKHALTER JOSEPH H ,  JONES ELDON M ,  RAWLINS ALBERT L ,  TENDICK FRANK H ,  HOLCOMB WALTER F

IPC: C07D215/44

CPC classification number: C07D215/44

公开(公告)号：US2474818A

公开(公告)日：1949-07-05

申请号：US55649644

申请日：1944-09-29

Applicant: PARKE DAVIS & CO

Inventor： BURCKHALTER JOSEPH H ,  JONES ELDON M ,  RAWLINS WALBERT L ,  TENDICK FRANK H ,  HOLCOMB WALTER F

IPC: C07D215/44

CPC classification number: C07D215/44

公开(公告)号：US20250002511A1

公开(公告)日：2025-01-02

申请号：US18707125

申请日：2022-11-04

Applicant: Georgiamune Inc.

Inventor： Samir KHLEIF ,  Mikayel MKRTICHYAN ,  Malcolm MACCOSS

IPC: C07F9/60 ,  C07D215/44 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: Compounds of Formula la, lb, Ic, Ila, lIb, lIc, Illa, Illb, IIIc, IVa, IVb, or IVc, or, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

公开(公告)号：US20240092800A1

公开(公告)日：2024-03-21

申请号：US18260721

申请日：2022-01-14

Applicant: GEORGETOWN UNIVERSITY

Inventor： Charbel MOUSSA ,  Christian WOLF ,  Balaraman KALUVU

IPC: C07D495/04 ,  A61K45/06 ,  A61P25/28 ,  C07D215/233 ,  C07D215/44 ,  C07D311/68

CPC classification number: C07D495/04 ,  A61K45/06 ,  A61P25/28 ,  C07D215/233 ,  C07D215/44 ,  C07D311/68

Abstract: Novel ubiquitin specific protease 13 (USP13) inhibitors are provided, along with methods for their use. The USP13 inhibitors described herein are useful in treating and/or preventing USP13-related diseases, such as neurodegenerative diseases and cancer. Also provided are methods for inhibiting USP13 in a cell using the compounds and compositions described herein.

公开(公告)号：US20240084102A1

公开(公告)日：2024-03-14

申请号：US18495426

申请日：2023-10-26

Applicant: DAIKIN INDUSTRIES, LTD.

Inventor： Tadashi KANBARA ,  Tsuyoshi NOGUCHI ,  Fumihiro KAMIYA ,  Daisuke OTA ,  Atsushi SUDO

IPC: C08K5/34 ,  C07D213/60 ,  C07D215/44 ,  C07D241/20 ,  C07D241/54 ,  C07D251/42 ,  C08L27/12

CPC classification number: C08K5/34 ,  C07D213/60 ,  C07D215/44 ,  C07D241/20 ,  C07D241/54 ,  C07D251/42 ,  C08L27/12

Abstract: A compound for use as a cross-linking agent represented by the following formula (1) wherein R1 is —SO2—, —O—, —CO—, an optionally substituted alkylene group, a group represented by the following formula (2) or a single bond; and two As are each independently an aromatic ring group containing a 5- or 6-membered aromatic ring and optionally containing a substituent, where the aromatic ring group contains a substituent in the case where the aromatic ring group is a monocyclic aromatic ring group containing a 6-membered aromatic hydrocarbon ring. Also disclosed is a composition containing the cross-linking agent.

公开(公告)号：US11884647B2

公开(公告)日：2024-01-30

申请号：US17072844

申请日：2020-10-16

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  ATENGEN, INC.

Inventor： Hui Sun ,  Pu Sun ,  Guo Cheng ,  Adrian Chichuen Au ,  Ming Zhong

IPC: C07D401/14 ,  A61P35/00 ,  C07D215/42 ,  C07D215/44 ,  C07D215/46 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/113 ,  C07D498/04 ,  C07H15/26

CPC classification number: C07D401/14 ,  A61P35/00 ,  C07D215/42 ,  C07D215/44 ,  C07D215/46 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/113 ,  C07D498/04 ,  C07H15/26

Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

公开(公告)号：US20230095341A1

公开(公告)日：2023-03-30

申请号：US17759806

申请日：2021-01-29

Applicant: GEORGETOWN UNIVERSITY

Inventor： Charbel MOUSSA ,  Christian WOLF ,  Balaraman KALUVU

IPC: C07D215/44 ,  A61P25/00 ,  C07D215/233 ,  C07D217/22 ,  C07C229/60 ,  A61K45/06

Abstract: Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a neurodevelop-mental disease, a myodegenerative disease, a prion disease, a lysosomal storage disease or cancer in a subject.